604 related articles for article (PubMed ID: 35777362)
21. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; Zhang B; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
Cell Rep; 2022 Nov; 41(5):111528. PubMed ID: 36302375
[TBL] [Abstract][Full Text] [Related]
22. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
[TBL] [Abstract][Full Text] [Related]
23. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
25. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
[TBL] [Abstract][Full Text] [Related]
26. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
[TBL] [Abstract][Full Text] [Related]
27. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
28. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Dijokaite-Guraliuc A; Das R; Zhou D; Ginn HM; Liu C; Duyvesteyn HME; Huo J; Nutalai R; Supasa P; Selvaraj M; de Silva TI; Plowright M; Newman TAH; Hornsby H; Mentzer AJ; Skelly D; Ritter TG; Temperton N; Klenerman P; Barnes E; Dunachie SJ; ; Roemer C; Peacock TP; Paterson NG; Williams MA; Hall DR; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
Cell Rep; 2023 Apr; 42(4):112271. PubMed ID: 36995936
[TBL] [Abstract][Full Text] [Related]
29. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
31. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
32. Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1.
Windsor IW; Tong P; Lavidor O; Moghaddam AS; McKay LGA; Gautam A; Chen Y; MacDonald EA; Yoo DK; Griffths A; Wesemann DR; Harrison SC
Sci Immunol; 2022 Aug; 7(74):eabo3425. PubMed ID: 35536154
[TBL] [Abstract][Full Text] [Related]
33. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.
Liu L; Casner RG; Guo Y; Wang Q; Iketani S; Chan JF; Yu J; Dadonaite B; Nair MS; Mohri H; Reddem ER; Yuan S; Poon VK; Chan CC; Yuen KY; Sheng Z; Huang Y; Bloom JD; Shapiro L; Ho DD
Immunity; 2023 Oct; 56(10):2442-2455.e8. PubMed ID: 37776849
[TBL] [Abstract][Full Text] [Related]
34. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
[TBL] [Abstract][Full Text] [Related]
35. A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5.
Duan M; Duan H; An Y; Zheng T; Wan S; Wang H; Zhao X; Dai L; Xu K; Gao GF
Emerg Microbes Infect; 2023 Dec; 12(1):e2179357. PubMed ID: 36803449
[TBL] [Abstract][Full Text] [Related]
36. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C; Turelli P; Ni D; Perez L; Lau K; Herate C; Marlin R; Lana E; Pellaton C; Raclot C; Esteves-Leuenberger L; Campos J; Farina A; Fiscalini F; Dereuddre-Bosquet N; Relouzat F; Abdelnabi R; Foo CS; Neyts J; Leyssen P; Lévy Y; Pojer F; Stahlberg H; LeGrand R; Trono D; Pantaleo G
Nat Microbiol; 2022 Sep; 7(9):1376-1389. PubMed ID: 35879526
[TBL] [Abstract][Full Text] [Related]
37. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
[TBL] [Abstract][Full Text] [Related]
38. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
39. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
40. Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays.
Passariello M; Esposito S; Manna L; Rapuano Lembo R; Zollo I; Sasso E; Amato F; De Lorenzo C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
